Association of antidepressants with cataracts and glaucoma: a disproportionality analysis using the reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS) pharmacovigilance database
Most of the investigated antidepressants were associated with a lower risk of cataract reporting. TCAs, brexanolone, esketamine, and opipramol were associated with greater odds of cataract. For most antidepressants, there was an insignificant increase in reports of ACG and OAG.
Authors
- Angela T.H. Kwan (ORCID: https://orcid.org/0000-0003-4013-1112)
- Bing Cao (ORCID: https://orcid.org/0000-0001-5963-2676)
- Rodrigo B. Mansur (ORCID: https://orcid.org/0000-0002-3968-3297)
- Gia Han Le (ORCID: https://orcid.org/0000-0001-6457-0086)
- Joshua D. Rosenblat (ORCID: https://orcid.org/0000-0002-4773-2191)
- Roger Ho (ORCID: https://orcid.org/0000-0001-9629-4493)
- Roger S. McIntyre (ORCID: https://orcid.org/0000-0003-4733-2523)
- Kayla M. Teopiz (ORCID: https://orcid.org/0000-0001-8429-6563)
- Taeho Greg Rhee (ORCID: https://orcid.org/0000-0003-4961-3361)
- Maj Vinberg (ORCID: https://orcid.org/0000-0002-5982-1335)
- Sonya Liao
- Sabrina Wong (ORCID: https://orcid.org/0009-0002-0928-3433)
Institutions
- University of Copenhagen (DK)
- University Health Network (CA)
- University of Connecticut (US)
- Southwest University (CN)
- University of Ottawa (CA)
- National University of Singapore (SG)
- University of Toronto (CA)
- Hong Kong University of Science and Technology (HK)
- Mental Health Services (DK)
- Yale University (US)
- Brain and Cognition Discovery Foundation (CA)
Publication Details
- Journal
- CNS Spectrums
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1017/s1092852924002360
- Citations
- 4
- Primary Topic
- Glaucoma and retinal disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.15
Funders
- Pfizer
- Sanofi
- Biogen
- Patient-Centered Outcomes Research Institute
- Purdue University
- Sunovion
- Physicians' Services Incorporated Foundation
- National University of Singapore
- National Natural Science Foundation of China
- University of Toronto
- Eisai
- Novo Nordisk
- H. Lundbeck A/S
- Bausch Health
- Substance Abuse and Mental Health Services Administration
- Allergan
- Department of Psychiatry, University of Toronto
- Canadian Institutes of Health Research
- National Institute of Mental Health
- Cilag